SCHEDULE: Laurence Lytton Updates Stake in Aprea Therapeutics

Laurence W. Lytton has updated his beneficial ownership filing for Aprea Therapeutics, Inc., reporting a 3.2% stake.

Summary

• Laurence W. Lytton has filed an amendment to his Schedule 13G, reporting his beneficial ownership of Aprea Therapeutics, Inc. common stock.
• As of June 30, 2026, Lytton beneficially owns 390,807 shares, representing 3.2% of the class.
• This ownership includes sole voting power over 322,220 shares and shared voting power over 68,587 shares.
• Similarly, Lytton has sole dispositive power over 322,220 shares and shared dispositive power over 68,587 shares.
• The filing states that these securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership without significant new financial or strategic information.

Positives

• Clear disclosure of beneficial ownership, providing transparency to the market.
• The filing indicates a stable, non-controlling stake, which can be viewed positively by management and other shareholders.

Negatives

• No new financial performance data or strategic updates are provided in this filing.
• The filing does not offer insights into the company's operational performance or future prospects.

Risks

• The filing does not explicitly mention any new risks.
• However, any investment in a biotechnology company like Aprea Therapeutics inherently carries risks related to drug development, clinical trials, regulatory approvals, and market competition.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for significant beneficial owners and do not typically reflect new strategic shifts or operational performance. For Aprea Therapeutics, a company in the biotechnology sector, such filings are common as institutional and individual investors adjust their positions.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant shareholder's stake.
• Management: Confirmation that the reported stake is not intended to influence control, which may be reassuring.

Next Steps

• Laurence W. Lytton will continue to report any further changes in his beneficial ownership of Aprea Therapeutics, Inc. common stock as required by SEC regulations.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Aprea Therapeutics, common stock, Laurence W. Lytton, stakeholder, investment